A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
|Articles|November 1, 2021
Daily OTC Pearl: Debrox (Carbamide Peroxide)
Author(s)Saro Arakelians, PharmD
Debrox helps to soften, loosen, and remove earwax.
Advertisement
OTC/Lifestyle Pearl of the Day: Debrox (Carbamide Peroxide)
Indication: Debrox is used to treat
Insight:
- Debrox helps to soften, loosen, and remove earwax.
- Too much earwax can block the ear canal and reduce hearing.
- This medication releases oxygen and starts to foam when it comes in contact with the
skin . - The foaming helps break up and remove the earwax.
- Directions: Apply this medication into the ear, usually twice daily, or as directed by a physician. Do not use this medication for more than 4 days at a time unless instructed by a physician.
- Adverse effects may include
rash ,itching /swelling (especially of the face/tongue /throat), severedizziness , andtrouble breathing .
Sources:
Advertisement
Related to this article
A Novo Nordisk-funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, though the findings cannot show causation.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
In SCOUT-HCM, mavacamten reduced the Valsalva LVOT gradient by 48 mm Hg versus placebo in adolescents. REMS, echo monitoring, and CYP interactions still apply in the new population.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1C reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
Pharmacist, Advocate, Ally: Delivering Comprehensive Gender-Affirming Care
3
Semaglutide 2 mg Tied to Lower MACE Risk Than Tirzepatide Switch
4
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
5